Shiny K. Kajal/LinkedIn
Mar 3, 2026, 17:04
Shiny K Kajal: Therapeutic Apheresis Is Redefining the Clinical Scope of Transfusion Medicine
Shiny K Kajal, Senior Resident at Adesh University, shared a post on LinkedIn:
“Post 29 – When most people think of transfusion medicine, they think of blood bags and compatibility testing.
But modern Immunohematology and Blood Transfusion goes far beyond that.
Therapeutic Apheresis allows selective removal of disease-causing components directly from circulation – offering rapid clinical benefit in several critical conditions.
Key Apheresis Modalities
- Therapeutic Plasma Exchange (TPE) – Removal of pathogenic plasma components
- Red Cell Exchange – Replacement of abnormal erythrocytes
- Leukapheresis – Rapid cytoreduction in leukocytosis
- Plateletpheresis – Control of extreme thrombocytosis
- LDL Apheresis – Removal of atherogenic lipoproteins
From autoimmune diseases to hematologic emergencies, therapeutic apheresis is redefining the clinical scope of transfusion medicine.
Not just transfusing blood — but therapeutically transforming it.”
Stay updated with Hemostasis Today.
-
Sep 11, 2026, 12:22The First New Treatment for Essential Thrombocythemia in Nearly 30 Years
-
Sep 11, 2026, 12:20When Thrombosis Affects the Kidneys – World Thrombosis Day
-
Sep 11, 2026, 11:24Haroun Gajraj: Polidocanol or STS – Choosing the Right Sclerosant
-
Sep 11, 2026, 10:53A Patient-Centred Approach to Haemophilia B Care – EAHAD
-
Sep 11, 2026, 09:51Alfredo Lozada: Pelacarsen Lowers Lp(a), But Does It Lower CV Risk?
-
Sep 11, 2026, 09:35Yasir Khan: Travel Related Blood Clots – What Are the Chances?
-
Sep 11, 2026, 08:02Mud Alvi: Restarting Antithrombotic Therapy After Hemorrhagic Transformation of Ischemic Stroke
-
Sep 11, 2026, 08:01Chaza Alaji: Factor X From Inherited Deficiency to Acquired Deficiency in AL Amyloidosis
-
Sep 11, 2026, 08:01Mariusz Kowalewski: Risk Stratification of Surgical Ablation During Minimally Invasive Mitral Valve Surgery for AFib